Linked Life Data

6978384

Source:http://linkedlifedata.com/resource/pubmed/id/6978384

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6978384rdf:typepubmed:Citationlld:pubmed
pubmed-article:6978384lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C0376315lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C0018591lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:6978384lifeskim:mentionsumls-concept:C1705535lld:lifeskim
pubmed-article:6978384pubmed:issue3lld:pubmed
pubmed-article:6978384pubmed:dateCreated1982-6-14lld:pubmed
pubmed-article:6978384pubmed:abstractText261 multiple sclerosis (MS) patients were HLA-A and -B typed and 94 were HLA-D typed. The results were compared to those of controls typed for HLA-A; HLA-B (356) and HLA-D (113). We confirm and extend earlier findings (Oger et al. 1980b) that some phenotypes could modulate the expression of the MS susceptibility gene linked to B7-DR2: DR3 was found together with DR2 in 12/94 MS and only 3/113 controls and could be marker for an "augmentor" gene. In contrast, B35 and DR1 as well as B12 and DR7 could be markers of protector genes. We compared typing results of patients subgrouped on clinical features. 61 patients with progressive evolution showed increased A1, A1-B8, B8-DR3 and A1-B8-DR3 when compared to 200 patients with remitting evolution. When compared to controls both groups showed increased B7 but only the remitting group showed increased DR2. 71 patients with "benign MS" showed increased B7-DR2 and A3-B7-DR2. 54 patients with "severe disease" showed increased DR3 and A1-B8-DR3 when compared to controls. Both groups showed increased B7 (49.2% and 44.4% versus 25.5% for controls). 120 patients treated greater than 5 years with azathioprine were divided into "no progression" and "progression" while treated. Both groups showed increased B7 when compared to controls. DR2 was increased only in the "no progression" group. B8-DR3 and A1-B8-DR3 were found increased in the "progression" group only. We conclude that two forms of MS exist with different HLA profiles.lld:pubmed
pubmed-article:6978384pubmed:languageenglld:pubmed
pubmed-article:6978384pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6978384pubmed:citationSubsetIMlld:pubmed
pubmed-article:6978384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6978384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6978384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6978384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6978384pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6978384pubmed:statusMEDLINElld:pubmed
pubmed-article:6978384pubmed:monthMarlld:pubmed
pubmed-article:6978384pubmed:issn0022-510Xlld:pubmed
pubmed-article:6978384pubmed:authorpubmed-author:MadigandMMlld:pubmed
pubmed-article:6978384pubmed:authorpubmed-author:GenetetBBlld:pubmed
pubmed-article:6978384pubmed:authorpubmed-author:FauchetRRlld:pubmed
pubmed-article:6978384pubmed:authorpubmed-author:SabouraudOOlld:pubmed
pubmed-article:6978384pubmed:authorpubmed-author:OgezJ RJRlld:pubmed
pubmed-article:6978384pubmed:issnTypePrintlld:pubmed
pubmed-article:6978384pubmed:volume53lld:pubmed
pubmed-article:6978384pubmed:ownerNLMlld:pubmed
pubmed-article:6978384pubmed:authorsCompleteYlld:pubmed
pubmed-article:6978384pubmed:pagination519-29lld:pubmed
pubmed-article:6978384pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:meshHeadingpubmed-meshheading:6978384-...lld:pubmed
pubmed-article:6978384pubmed:year1982lld:pubmed
pubmed-article:6978384pubmed:articleTitleHLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.lld:pubmed
pubmed-article:6978384pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6978384pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6978384lld:pubmed